Skip to main content
ARAY
NASDAQ Industrial Applications And Services

Accuray Reports Steep Q2 Losses, Revenue Decline Amid Restructuring and Nasdaq Delisting Threat

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.578
Mkt Cap
$62.066M
52W Low
$0.5
52W High
$2.33
52W Position info
16% above low
Off High info
75% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ARAY sits 16% above its 52-week low of $0.5.

Summary

Accuray Inc. reported a significant net loss of $13.8 million for Q2 FY26 and a 12% revenue decline, alongside ongoing restructuring efforts and previously disclosed material weaknesses in internal controls and Nasdaq non-compliance.


Key Events · Earnings and Guidance · ARAY

  • Significant Financial Deterioration

    Accuray reported a net loss of $13.77 million for the three months ended December 31, 2025, a substantial decline from a $2.54 million net income in the prior-year period. Revenue decreased by 12% to $102.24 million for the quarter, and by 10% to $196.18 million for the six-month period, primarily due to lower product shipments to China.

  • Gross Margin Compression

    Gross profit margin fell sharply to 23.5% in Q2 FY26 from 36.1% in the prior-year quarter, primarily due to decreased product unit sales and an unfavorable product mix.

  • Ongoing Restructuring Plan

    The company implemented a FY26 Restructuring Plan, including a 15% global workforce reduction during Q2 FY26, incurring $6.08 million in restructuring charges for the quarter. Total restructuring charges for the six months ended December 31, 2025, amounted to $8.89 million, with an expected total of approximately $13 million for fiscal year 2026.

  • Material Weaknesses in Internal Controls Confirmed

    The company confirmed two material weaknesses in its internal controls over financial reporting as of December 31, 2025, related to footnote disclosures and GAAP presentation analysis. This led to the restatement of financial statements for fiscal year 2025 and Q1 FY26, as disclosed in concurrent 10-K/A and 10-Q/A filings.


Analysis · ARAY · Industrial Applications And Services

Accuray's Q2 FY26 results confirm a significant deterioration in financial performance, with a substantial net loss and sharp decline in revenue and gross margins. This follows recent disclosures of financial restatements and a Nasdaq non-compliance notice, indicating severe operational and compliance challenges. The ongoing restructuring, including significant workforce reductions, highlights the company's efforts to address its financial distress, but the immediate impact is a deepening loss. Investors face heightened risks related to the company's ability to achieve profitability, maintain its Nasdaq listing, and navigate a challenging macroeconomic environment.

At the time of this filing, ARAY was trading at $0.58 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $62.1M. The 52-week trading range was $0.50 to $2.33. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARAY - Latest Insights

ARAY
Jun 04, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3655
Real-time Price: $0.2427 info
Change: -$0.1228 (-34%) info
Market Cap: $28.956M info
ARAY
May 22, 2026, 3:57 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.3077
Real-time Price: $0.2427 info
Change: -$0.065 (-21%) info
Market Cap: $28.956M info
ARAY
May 06, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.4105
Real-time Price: $0.2427 info
Change: -$0.1678 (-41%) info
Market Cap: $28.956M info
ARAY
May 06, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.4724
Real-time Price: $0.2427 info
Change: -$0.2297 (-49%) info
Market Cap: $28.956M info
ARAY
Apr 28, 2026, 9:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4455
Real-time Price: $0.2427 info
Change: -$0.2028 (-46%) info
Market Cap: $28.956M info